What Pfizer’s $11.4B Purchase Means For The Future of Biopharma

Pfizer Inc. announced Monday that it would purchase Array Biopharma Inc. for $11.4 billion in cash, providing the New York-based pharmaceutical front-runner access to an entirely new line of products–specifically, drugs that target cancer.

Pfizer has been monopolizing the novel cancer drugs and gene therapies arena in an attempt to keep up with its competitors. The deal will dilute shares by .04 to .05 for the remainder of this year and through 2020 and is expected to add earnings by 2022.

So, what does this acquisition mean for the future of biopharma?

Cutting edge companies developing novel cancer drugs, like Propanc Biopharma, Inc. (PPCB), can potentially expect sparked investor interest following this billion-dollar purchase.

Propanc Biopharma, Inc. is an Australian-based biopharmaceutical company that is focused on the development of new cancer drugs targeting high-risk patients. Although they are currently transitioning from preclinical to clinical stage, their  lead drug product candidate will initially target patients suffering from pancreatic, ovarian, and colorectal cancers, which still have a large, unmet medical need.

Their approach is based on a pancreatic proenzyme formulation that prevents tumor recurrence and metastasis, the main cause of patient death from cancer. Their lead drug product candidate, PRP, converts cancerous cells back towards normal cell behavior.

These biotech companies are making great progress: Propanc BioPharma, Inc. (OTCQB: PPCB), Verastem, Inc. (Nasdaq: VSTM), NeuroMetrix, Inc. (Nasdaq: NURO), Caladrius Biosciences, Inc. ( Nasdaq:CLBS), Stemline Therapeutics, Inc. (Nasdaq: STML), Celsion Corporation (Nasdaq: CLSN)

Propanc BioPharma, Inc. (OTCQB: PPCB), (Market Cap: $3.129M, current share price: $0.007) Propanc BioPharma, Inc. is a biopharmaceutical company developing new cancer drugs for patients suffering from recurring and metastatic cancer, recently announced it had completed a scientific advice meeting with the MHRA in reference to PRP, which has been designated as an Orphan Drug by the FDA for Pancreatic Cancer. Additionally, the company went through a number of topics in preparation for a Clinical Trial Application for PRP with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, and the first in human study that the company plans to conduct either in the UK, or Australia. PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergistic ratio that targets solid tumors.

Verastem, Inc. (Nasdaq: VSTM), (Market Cap: $129.284M, current share price: $1.75) Verastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company’s lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma.

NeuroMetrix, Inc. (Nasdaq: NURO), (Market Cap: $4.718M, current share price: $0.53) NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain.

Caladrius Biosciences, Inc. ( Nasdaq:CLBS), (Market Cap: $30.108M, current share price: $2.90) Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell-based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products.

Stemline Therapeutics, Inc. (Nasdaq: STML), (Market Cap: $654.834M, current share price: $14.99) Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company’s preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor.

Celsion Corporation (Nasdaq: CLSN), (Market Cap: $37.073M, current share price: $1.81)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Moreover, Han Tao, General Manager of China Capital Investments recently said in an interview, “Investors are positive about biopharma prospects, especially after the launch of recent IPO (initial public offering) policies in Hong Kong and Shanghai, which appear to be a great support for companies that are strong in development but lack enough funds.”

There is no doubt that this recent acquisition will open the door for other forward-thinking investors to add and enhance their portfolios with cutting-edge biopharma companies.

Legal Disclaimer: 

This article was written by Regal Consulting, LLC (“Regal Consulting”).  Regal Consulting expects to be paid $3,000 for the article directly from PPCB.  All payments were made directly by Propanc Biopharma, Inc. (PPCB) to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of.  Regal Consulting also paid one thousand dollars cash to to distribute this article.  Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice.  This article is based on public information and the opinions of Regal Consulting. PPCB was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein.  Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice. legal disclaimer/

 Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States